Linked Life Data

15958628

Source:http://linkedlifedata.com/resource/pubmed/id/15958628

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2005-6-16
pubmed:abstractText
To evaluate the safety and biological activity of three different doses of marimastat given for 6 months to patients with biochemically relapsed prostate cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4437-43
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15958628-Aged, pubmed-meshheading:15958628-Analysis of Variance, pubmed-meshheading:15958628-Arthralgia, pubmed-meshheading:15958628-Disease Progression, pubmed-meshheading:15958628-Dose-Response Relationship, Drug, pubmed-meshheading:15958628-Double-Blind Method, pubmed-meshheading:15958628-Enzyme Inhibitors, pubmed-meshheading:15958628-Humans, pubmed-meshheading:15958628-Hydroxamic Acids, pubmed-meshheading:15958628-Male, pubmed-meshheading:15958628-Metalloendopeptidases, pubmed-meshheading:15958628-Middle Aged, pubmed-meshheading:15958628-Neoplasm Recurrence, Local, pubmed-meshheading:15958628-Prospective Studies, pubmed-meshheading:15958628-Prostate-Specific Antigen, pubmed-meshheading:15958628-Prostatic Neoplasms, pubmed-meshheading:15958628-Time, pubmed-meshheading:15958628-Treatment Outcome
pubmed:year
2005
pubmed:articleTitle
Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial.
pubmed:affiliation
Department of Radiation Oncology and Molecular Sciences, Division of Medical Oncology and Biostatistics and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II, Clinical Trial, Phase I